

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**Current Report  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) June 24, 2019**

---

**HOLOGIC, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

---

**DELAWARE**  
(State or Other Jurisdiction  
of Incorporation)

**1-36214**  
(Commission  
File Number)

**04-2902449**  
(I.R.S. Employer  
Identification No.)

**250 Campus Drive, Marlborough, MA**  
(Address of Principal Executive Offices)

**01752**  
(Zip Code)

**(508) 263-2900**  
(Registrant's Telephone Number, Including Area Code)  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, \$.01 par value</b>	<b>HOLX</b>	<b>The NASDAQ Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 24, 2019, Thomas A. West, Division President, Diagnostics, of Hologic, Inc. (“Hologic” or the “Company”) tendered his resignation from the Company, effective July 1, 2019. He is leaving Hologic to assume the role of Chief Executive Officer at another publicly traded company. Hologic extends its appreciation to Mr. West for his contributions and wishes him success in his next position.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 27, 2019

HOLOGIC, INC.

By: /s/ John M. Griffin

John M. Griffin  
General Counsel